Maddi Hebebrand, MC, Associate Editor

Karan Lal, DO, MS, FAAD, is a double-board certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona.

Click here to answer today's poll and read more about providing patients with multidisciplinary care.

Researchers found evidence from numerous studies claiming LDI could improve rosacea symptoms and decrease flare-ups.

Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.

The organization is highlighting stories and resources during Acne Awareness Month through the power of social media.

Dermatology Times is recapping our top expert interviews from the month of May.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

The study is the first to be approved by the European Medicines Agency to perform human clinical trials with a novel therapeutic mAb.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.

A new acne-specific HRQoL questionnaire developed in Europe could help to create more comprehensive, individualized treatment plans.

A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.

Results of a recent study show RECAP's impact on adult Asian patients with AD.